Folic acid
Based on 25 publication(s) in Google Scholar
Folic acid (Vitamin B9) is a orally active essential nutrient from the B complex group of vitamins. Folic acid shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency.
For research use only. We do not sell to patients.
- Purity: 99.02%
- CAS No.: 59-30-3
- Formula: C19H19N7O6
- Molecular Weight:441.40
-
Storage:
RT, protect from light.
In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Folic acid
More- Bioact Mater. 2025 Apr 8:50:152-170. [Abstract]
- Nat Commun. 2024 Nov 12;15(1):9529. [Abstract]
- Adv Sci (Weinh). 2024 Oct 25:e2410769. [Abstract]
- J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]
- J Nanobiotechnology. 2025 Dec 5. [Abstract]
- Research (Wash D C). 2025 May 12:8:0653 [Abstract]
- Cell Rep Med. 2023 Mar 21;4(3):100953. [Abstract]
- Br J Cancer. 2023 Aug;129(3):531-540. [Abstract]
- Anal Chem. 2025 May 13;97(18):9827-9835. [Abstract]
- JCI Insight. 2022 Apr 8;7(7):e152330. [Abstract]
- Food Biosci. 2026 Mar 23.
- Biochem Pharmacol. 2025 Oct:240:117120. [Abstract]
- Food Funct. 2026 Apr 27;17(8):3587-3599. [Abstract]
- Drug Des Devel Ther. 2024 Dec 21:18:6223-6241. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Sci Rep. 2025 Apr 16;15(1):13119. [Abstract]
- Sci Rep. 2025 Jan 27;15(1):3346. [Abstract]
- Microbiol Spectr. 2023 Sep 21;11(5):e0267123. [Abstract]
- Neurotox Res. 2020 Dec;38(4):859-870. [Abstract]
- J Pharm Pharmacol. 2025 Aug 21:rgaf072. [Abstract]
- Ren Fail. 2024 Dec;46(1):2329257. [Abstract]
- In Vitro Cell Dev Biol Anim. 2025 Aug;61(7):774-788. [Abstract]
- SSRN. 2025 Sep 17.
- SSRN. 2025 Jan 14.
- bioRxiv. 2023 Jun 1.
-
WB
-
WB
-
IHC
-
RT-PCR
-
Histological Imaging/Staining
All DNA/RNA Synthesis Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
Microbial Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| K562 | IC50 |
290 μM
Compound: folate
|
Ability to inhibit thymidylate synthase derived from human leukemia K562 cells
Ability to inhibit thymidylate synthase derived from human leukemia K562 cells
|
[PMID: 3470522] |
| KB | IC50 |
0.5 μM
Compound: folic acid
|
Photocytotoxicity against human KB cells overexpressing folate receptor assessed as cell viability incubated for 24 hrs followed by halogen light illumination measured after 20 mins by MTT assay
Photocytotoxicity against human KB cells overexpressing folate receptor assessed as cell viability incubated for 24 hrs followed by halogen light illumination measured after 20 mins by MTT assay
|
[PMID: 24088087] |
| L1210 | IC50 |
>10 mM
Compound: Folic acid
|
Inhibitory activity against growth of L1210 leukemia cells in culture
Inhibitory activity against growth of L1210 leukemia cells in culture
|
[PMID: 1560436] |
| L1210 | IC50 |
>0.001 M
Compound: table II
|
Inhibitory activity against thymidylate synthase in the intact L1210 cells
Inhibitory activity against thymidylate synthase in the intact L1210 cells
|
[PMID: 3100797] |
| L1210 | IC50 |
0.00018 M
Compound: table II
|
Inhibitory activity against the thymidylate synthase in the Permeabilized L1210 cells
Inhibitory activity against the thymidylate synthase in the Permeabilized L1210 cells
|
[PMID: 3100797] |
| L1210 | IC50 |
0.18 mM
Compound: table II
|
Inhibitory activity against the thymidylate synthase in the Permeabilized L1210 cells
Inhibitory activity against the thymidylate synthase in the Permeabilized L1210 cells
|
[PMID: 3100797] |
| MOLT-4 | IC50 |
>100 μM
Compound: Folic acid
|
Compound was evaluated for inhibition of MTX influx into MOLT-4 cells
Compound was evaluated for inhibition of MTX influx into MOLT-4 cells
|
[PMID: 1895294] |
Folic acid plays a critical role in the prevention of chromosome breakage and hypomethylation of DNA[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:30-40 g swiss mice[2]
-
Dosage:10, 50, 100 mg/kg
-
Administration:Oral administration
-
Result:Decreased the immobility time in the forced swimming test (FST) (F324=11.21) and produced a significant effect in the immobility time in the tail suspension test (TST) (F3,20=5.71).
-
Animal Model:30-40 g swiss mice[2]
-
Dosage:1-10 nmol/site
-
Administration:Intracerebroventrical injection
-
Result:Decreased the immobility time of mice in the FST (F3,22=12.31) and TST (F3,22=5.50).
-
Animal Model:Virgin female Wistar rats[3]
-
Dosage:1, 5 mg/kg (180 g/kg protein with 1 mg/kg folic acid or 90 g/kg casein with 1, 5 mg/kg folic acid)
-
Administration:Oral administration
-
Result:Prevented epigenetic modification of hepatic gene expression in the offspring.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Folic acid can be used to induce acute kidney injury models. In rats, oral administration results in an AUC of 1.4 μg h/mL, with an oral bioavailability of 35%[5].
Administration: 300mg/ml • i.p. • single dose
(2) Plasma was collected and analyzed at days 2, 4, 7, 14 and 28 after folic acid administration.
Individual phenotypic change: The ratio of kidney weight to total rat weight was detected.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 59-30-3
-
Appearance Solid
-
Molecular Weight 441.40
-
Formula C19H19N7O6
-
Color Light yellow to yellow
-
SMILES
O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(NCC2=CN=C3N=C(N)NC(C3=N2)=O)C=C1)=O
-
Synonyms
Vitamin B9; Vitamin M
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
RT, protect from light
In solvent -80°C 1 year -20°C 6 months
Publications (25)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
Bidirectional modulation of glycolysis using a multifunctional nanocomposite hydrogel promotes bone fracture healing in type 2 diabetes mellitus. [Abstract]2025 Apr 8:50:152-170. PMID: 40256330 -
Nat Commun
2024 Nov 12;15(1):9529. PMID: 39532843 -
Adv Sci (Weinh)
Gene Therapy for Inflammatory Cascade in Intrauterine Injury with Engineered Extracellular Vesicles Hybrid Snail Mucus-enhanced Adhesive Hydrogels. [Abstract]2024 Oct 25:e2410769. PMID: 39454114 -
J Adv Res
c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis. [Abstract]2025 Dec 8:S2090-1232(25)00996-8. PMID: 41371401
Folic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]
Epithelial junctional proteins were upregulated by Folic acid (30 mg/kg) treated.
Folic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]
Decreased expression of mesenchymal markers, MMPs, and EMT regulators after Folic acid (30 mg/kg) administration.
Folic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]
Folic acid (30 mg/kg) restored epithelial architecture, as evidenced by the increase in crypt integrity, maintenance of goblet cells.
-
J Nanobiotechnology
Folate-modified biomimetic nanovesicles loaded with a PU.1 inhibitor alleviate atherosclerosis by suppressing inflammation. [Abstract]2025 Dec 5. PMID: 41345629 -
Research (Wash D C)
Creating Chemiluminescence Signature Arrays Coupled with Machine Learning for Alzheimer's Disease Serum Diagnosis. [Abstract]2025 May 12:8:0653 PMID: 40357359 -
Cell Rep Med
Gestational palmitic acid suppresses embryonic GATA-binding protein 4 signaling and causes congenital heart disease. [Abstract]2023 Mar 21;4(3):100953. PMID: 36809766 -
Br J Cancer
2023 Aug;129(3):531-540. PMID: 37369845 -
Anal Chem
Ultrahigh Flow Regulated Discharge Coupling with Targeted Mass Spectrometry Analysis: Real Time Capturing Biomolecules in Exhaled Breath. [Abstract]2025 May 13;97(18):9827-9835. PMID: 40302637 -
JCI Insight
2022 Apr 8;7(7):e152330. PMID: 35230979
Folic acid purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 Apr 8;7(7):e152330. [Abstract]
mRNA levels of TGF-β1, α-SMA, and fibronectin in the kidney of CTL, Folic acid (FAN) (250 mg/kg, IP, 7 days), and FAN+GsMTx4 mice.
Folic acid purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 Apr 8;7(7):e152330. [Abstract]
Photomicrographs of Masson’s staining in the kidney of CTL, Folic acid (FAN) (250 mg/kg, IP, 7 days), and FAN+GsMTx4 mice.
-
-
Biochem Pharmacol
Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]2025 Oct:240:117120. PMID: 40623460 -
Food Funct
Folic acid alleviates endothelial dysfunction caused by T2DM-induced ferroptosis by activating the SIRT6/NRF2/GPX4 signaling pathway. [Abstract]2026 Apr 27;17(8):3587-3599. PMID: 41906715 -
Drug Des Devel Ther
Network Pharmacology and Metabolomics Reveal Anti-Ferroptotic Effects of Curcumin in Acute Kidney Injury. [Abstract]2024 Dec 21:18:6223-6241. PMID: 39722679 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Sci Rep
Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK cell cytotoxicity via TNF-α. [Abstract]2025 Apr 16;15(1):13119. PMID: 40240368 -
Sci Rep
UHRF1 promotes epithelial-mesenchymal transition mediating renal fibrosis by activating the TGF-β/SMAD signaling pathway. [Abstract]2025 Jan 27;15(1):3346. PMID: 39870702 -
Microbiol Spectr
Potential quorum-sensing inhibitor of Hafnia alvei H4-theaflavin-3,3´-digallate analyzed by virtual screening and molecular simulation. [Abstract]2023 Sep 21;11(5):e0267123. PMID: 37732782 -
Neurotox Res
2020 Dec;38(4):859-870. PMID: 32415528 -
J Pharm Pharmacol
Folate-chitosan nanoparticle delivery of cannabidiol for targeted triple-negative breast cancer therapy. [Abstract]2025 Aug 21:rgaf072. PMID: 40838692 -
Ren Fail
The relationship between thiamin, folic acid and cognitive function in a rat model of uremia. [Abstract]2024 Dec;46(1):2329257. PMID: 38482596 -
In Vitro Cell Dev Biol Anim
5-Methoxytryptophan improves cerebrovascular injury induced by chronic kidney disease through NF-κB pathway. [Abstract]2025 Aug;61(7):774-788. PMID: 40632423 -
-
-
Solvent & Solubility
1M NaOH : 100 mg/mL (226.55 mM; Need ultrasonic)
DMSO : 33.33 mg/mL (75.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 300 mM Sodium bicarbonate in Water
Solubility: 50 mg/mL (113.28 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.71 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Butterworth CE Jr, et al. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989 Aug;50(2):353-8. [Content Brief]
[2]. Brocardo PS, et al. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology. 2008 Feb;54(2):464-73. [Content Brief]
[3]. Lillycrop KA, et al. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005 Jun;135(6):1382-6. [Content Brief]
[4]. Pietrzik K, et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010 Aug;49(8):535-48. [Content Brief]
[6]. Aparicio-Trejo OE, et al. Chronic impairment of mitochondrial bioenergetics and β-oxidation promotes experimental AKI-to-CKD transition induced by folic acid. Free Radic Biol Med. 2020 Jul;154:18-32. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 1M NaOH | 1 mM | 2.2655 mL | 11.3276 mL | 22.6552 mL | 56.6380 mL |
| 5 mM | 0.4531 mL | 2.2655 mL | 4.5310 mL | 11.3276 mL | |
| 10 mM | 0.2266 mL | 1.1328 mL | 2.2655 mL | 5.6638 mL | |
| 15 mM | 0.1510 mL | 0.7552 mL | 1.5103 mL | 3.7759 mL | |
| 20 mM | 0.1133 mL | 0.5664 mL | 1.1328 mL | 2.8319 mL | |
| 25 mM | 0.0906 mL | 0.4531 mL | 0.9062 mL | 2.2655 mL | |
| 30 mM | 0.0755 mL | 0.3776 mL | 0.7552 mL | 1.8879 mL | |
| 40 mM | 0.0566 mL | 0.2832 mL | 0.5664 mL | 1.4159 mL | |
| 50 mM | 0.0453 mL | 0.2266 mL | 0.4531 mL | 1.1328 mL | |
| 60 mM | 0.0378 mL | 0.1888 mL | 0.3776 mL | 0.9440 mL | |
| 1M NaOH | 80 mM | 0.0283 mL | 0.1416 mL | 0.2832 mL | 0.7080 mL |
| 100 mM | 0.0227 mL | 0.1133 mL | 0.2266 mL | 0.5664 mL |